Population-based study of competing mortality in head and neck cancer

Journal of Clinical Oncology

Volumn 29, Issue 26, 2011, Pages 3503-3509

  Rose, Brent S ^a   Jeong, Jong Hyeon ^b   Nath, Sameer K ^a   Lu, Sharon M ^a   Mell, Loren K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HIGH RISK POPULATION; HUMAN; HYPOPHARYNX; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NASOPHARYNX; NEGRO; NONSURGICAL INVASIVE THERAPY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; SAMPLE SIZE; SEX DIFFERENCE; SINGLE PARENT; SOCIOECONOMICS; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; UNITED STATES;

EID: 80052981071     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.7301     Document Type: Article

References (37)

1. International Agency for Research on Cancer: Globocan 2008. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#
2. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
3. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003 (Pubitemid 37464533)
4. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
5. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004 (Pubitemid 38580197)
6. Mell LK, Dignam JJ, Salama JK, et al: Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 28:15-20, 2010
7. Argiris A, Brockstein BE, Haraf DJ, et al: Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10:1956-1962, 2004 (Pubitemid 38375553)
8. Mell LK, Weichselbaum RR: More on cetuximab in head and neck cancer. N Engl J Med 357:2201-2202, 2007 (Pubitemid 350146125)
9. Pintilie M: Competing Risks: A Practical Perspective. John Wiley & Sons, Chichester, United Kingdom, 2006, pp 115-126
10. Mell LK, Jeong JH: Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol 28:4297-4299, 2010
11. Dignam JJ, Kocherginsky MN: Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027-4034, 2008
12. Latouche A, Porcher R, Chevret S, et al: Sample size formula for proportional hazards modelling of competing risks. Stat Med 23:3263-3274, 2004 (Pubitemid 39462086)
13. Latouche A, Porcher R: Sample size calculations in the presence of competing risks. Stat Med 26:5370-5380, 2007 (Pubitemid 351193567)
14. Pintilie M: Competing Risks: A Practical Perspective. John Wiley & Sons, Chichester, United Kingdom, 2006, pp 192-195
15. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch: Surveillance, Epidemiology, and End Results Program Limited-Use Data (1973-2004), released April 2007. http://www.seer.cancer.gov
16. Korn EL, Dorey FJ: Applications of crude incidence curves. Stat Med 11:813-829, 1992
17. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
18. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
19. Harrell FE, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 247:2543-2546, 1982 (Pubitemid 12155954)
20. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
21. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
22. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007 (Pubitemid 350005152)
23. Vermorken JB, Remenar E, Van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007 (Pubitemid 350005151)
24. Kent DM, Hayward RA: Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA 298:1209-1212, 2007 (Pubitemid 47403108)
25. Kent DM, Alsheikh-Ali A, Hayward RA, et al: Competing risk and heterogeneity of treatment effect in clinical trials. Trials 9:30, 2008
26. Glasziou PP, Irwig LM: An evidence based approach to individualising treatment. BMJ 311:1356-1359, 1995
27. Rothwell PM: Can overall results of clinical trials be applied to all patients? Lancet 345:1616-1619, 1995
28. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355:949-955, 2000 (Pubitemid 30148259)
29. Pignon JP, le Maître A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
30. Bourhis J, Overgaard J, Audry H, et al: Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368:843-854, 2006 (Pubitemid 44292807)
31. Lachin JM, Foulkes MA: Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42:507-519, 1986
32. Piccirillo JF, Tierney RM, Costas I, et al: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441-2447, 2004 (Pubitemid 38669187)
33. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000 (Pubitemid 30365531)
34. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008 (Pubitemid 351480538)
35. Kircher T, Nelson J, Burdo H, et al: The autopsy as a measure of accuracy of the death certificate. N Engl J Med 313:1263-1269, 1985 (Pubitemid 16217049)
36. Percy C, Stanek E III, Gloeckler L, et al: Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 71:242-250, 1981 (Pubitemid 11146407)
37. Percy CL, Miller BA, Gloeckler Ries LA, et al: Effect of changes in cancer classification and the certificates on trends in cancer mortality. Ann N Y Acad Sci 609:87-99, 1990